Compound: Opiorphin
SMILES: O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)N)CCCNC(=N)N)Cc1ccccc1)CO)CCCNC(=N)N
InChIKey: TWWFCOBVAKAKIT-SXYSDOLCSA-N
Synonyms: Opiorphin, L-Glutaminyl-L-arginyl-L-phenylalanyl-L-seryl-L-arginine, RefChem:168393, glutaminyl-arginyl-phenylalanyl-seryl-arginine, 864084-88-8, MFCD09752700, (2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]pentanoic acid, CHEMBL2022225, human opiorphin, C29H48N12O8, Opiorphin trifluoroacetate salt, Opiorphin?, QRFSR peptide, Gln-Arg-Phe-Ser-Arg, OPIORPHIN (HUMAN), B73XKF7SAQ, H-Gln-Arg-Phe-Ser-Arg-OH, SCHEMBL20257129, SCHEMBL29529332, GTPL11538, CHEBI:177467, DTXSID901027119, BDBM50382499, AKOS037646654, HY-W345510, AC-38366, AS-70071, DA-76445, FO109858, SY367292, CS-0456478, D93123, F776529, Q416529, L-Arginine, L-glutaminyl-L-arginyl-L-phenylalanyl-L-seryl-, (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,5-diamino-5-oxo-pentanoyl]amino]-5-guanidino-pentanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-propanoyl]amino]-5-guanidino-pentanoic acid, (2S,5S,8S,11S,14S)-14,17-Diamino-8-benzyl-2,11-bis(3-guanidinopropyl)-5-(hydroxymethyl)-4,7,10,13,17-pentaoxo-3,6,9,12-tetraazaheptadecan-1-oic Acid
Theoretical properties:
molecular_formula: C29H48N12O8
molecular_weight: 692.8 g/mol
exact_mass: 692.37180654 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 12
hydrogen_bond_acceptor_count: 11
rotatable_bond_count: 23
heavy_atom_count: 49
topological_polar_surface_area: 372 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Opiorphin is an oligopeptide.
chembl: OPIORPHIN is a protein listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: Opiorphin is an endogenous chemical compound first isolated from human saliva. Initial research with  mice shows the compound has a painkilling effect greater than that of morphine. It works by stopping the normal breakup of enkephalins, natural pain-killing opioids in the spinal cord. It is a relatively simple molecule consisting of a five-amino acid polypeptide, Gln-Arg-Phe-Ser-Arg (QRFSR).
Opiorphin pentapeptide originates from the N-terminal region of the protein PROL1 (proline-rich, lacrimal 1). Opiorphin inhibits three proteases: neutral ecto-endopeptidase (MME), ecto-aminopeptidase N (ANPEP)
and perhaps also a dipeptidyl peptidase DPP3.
Such action extends the duration of enkephalin effect where the natural pain killers are released physiologically in response to specific potentially painful stimuli, in contrast with administration of narcotics, which floods the entire body and causes many undesirable adverse reactions, including addiction liability and constipation.
In addition, opiorphin may exert anti-depressive and antipanic action.
Therapeutic application of opiorphin in humans would require modifying the molecule to avoid its rapid degradation in the intestine and its poor penetration of the blood–brain barrier. This  modification is done in the body by transformation of N-terminal glutamine into pyroglutamate. This form preserves the analgesic properties of opiorphin but with increased pharmaceutical stability.